Back from irreversibility: use of percutaneous cardiopulmonary bypass for treatment of shock from refractory anaphylaxis during coronary intervention.
Anaphylaxis during diagnostic catheterization and coronary intervention is a rare and potentially life-threatening complication. Fortunately, with standard intervention, fatality is rare. We report a case of medically refractory anaphylaxis during a coronary intervention that ultimately responded to percutaneous cardiopulmonary bypass (CPB). The proposed mechanics and use of CPB for shock are discussed.
Chengot
Thomas
T
Cardiology Department, Winthrop-University Hospital, Mineola, NY 11501, USA.
Goncalves
John
J
Marzo
Kevin
K
D054058:Acute Coronary Syndrome / Q000175:diagnosis / Q000628:therapy; D000322:Adrenergic Agonists / Q000627:therapeutic use; D000368:Aged; D000707:Anaphylaxis / Q000209:etiology* / Q000601:surgery*; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D002315:Cardiopulmonary Bypass; D003287:Contrast Media / Q000009:adverse effects*; D004837:Epinephrine / Q000627:therapeutic use; D006801:Humans; D007022:Hypotension / Q000139:chemically induced / Q000188:drug therapy; D008297:Male; D016896:Treatment Outcome
D000322:Adrenergic Agonists; D003287:Contrast Media; D004837:Epinephrine